Appointments: Changes At Merck KGaA, Servier, Unum and Aduro
The latest biopharma industry appointments include a new chief patient officer at Servier, executives at Merck KGaA, Unum and Aduro, as well as several board updates.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The foundation is donating to help supply Merck/Ridgeback’s antiviral to low-income nations; also Pfizer got one step closer to full approval for booster shots of Comirnaty, while the FDA authorized Moderna and J&J boosters, and Daiichi Sankyo made progress on its own mRNA vaccine candidate. Shionogi's once-daily oral antiviral is also moving forward.
New leaders in regulatory affairs and manufacturing at Pharnext SA and promotions at Abeona Therapeutics are among recent executive changes in the industry. Meanwhile, new directors were appointed at Onxeo SA, Avalo Therapeutics and Spero Therapeutics, among others.